News Room

EyePoint Pharmaceuticals Enters Lease Agreement for the Construction of a Commercial Manufacturing Facility for Global Product Supply of EYP-1901 and YUTIQ

1-23-23

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

1-17-23

EyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines

1-5-23

EyePoint Pharmaceuticals Promotes Jay S. Duker, M.D. to President and Chief Operating Officer

1-4-23

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

12-16-22

EyePoint Pharmaceuticals Ranked Among Fastest-Growing Companies in North America on the 2022 Deloitte Technology Fast 500™

11-16-22

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

11-16-22

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

11-7-22

EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments

11-2-22

EyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022

10-26-22

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

10-17-22

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy

9-29-22

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

9-16-22

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

9-6-22

EyePoint Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Developments

8-3-22

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

8-2-22

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD

8-1-22

EyePoint Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022

7-27-22

EyePoint Pharmaceuticals Investor Day to Highlight EYP-1901 and Durasert® Technology Developments and Provide a Financial Update

7-18-22

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

7-18-22

EyePoint Pharmaceuticals Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

7-15-22

EyePoint Pharmaceuticals to Host Investor Day on July 18, 2022

7-11-22

EyePoint Pharmaceuticals Appoints Karen Zaderej to Board of Directors

7-11-22

EyePoint Pharmaceuticals Announces Election of Tony Adamis, M.D. to Board of Directors

6-23-22

EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of New Drug Application by China’s NMPA for YUTIQ® for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

6-21-22

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

6-16-22

EyePoint Pharmaceuticals to Present 12-Month Results from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD at the American Society of Retina Specialists 2022 Annual Meeting

6-10-22

EyePoint Pharmaceuticals to Present at the H.C Wainwright Global Healthcare Investment Conference

5-17-22

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

5-16-22

EyePoint Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Developments

5-4-22

EyePoint Pharmaceuticals Announces Expanded License Agreement with Betta Pharmaceuticals for EYP-1901 in China, Hong Kong, Macau and Taiwan

5-4-22

EyePoint Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022

4-27-22

EyePoint Pharmaceuticals to Participate in Fireside Chat at the B. Riley 2022 Virtual Neuro & Ophthalmology Conference

4-21-22

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

4-18-22

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

3-16-22

EyePoint Pharmaceuticals Announces Debt Refinancing with $45M Credit Facilities from Silicon Valley Bank

3-9-22

EyePoint Pharmaceuticals Appoints Isabelle Lefebvre as Chief Regulatory Officer

3-7-22

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Developments

3-3-22

EyePoint Pharmaceuticals to Participate in Fireside Chat at the Cowen 42nd Annual Health Care Conference

3-1-22

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022

2-24-22

EyePoint Pharmaceuticals Announces Updated Positive Interim Safety and Efficacy Data from Ongoing Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

2-12-22

EyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievements

1-10-22

EyePoint Pharmaceuticals Appoints Michael C. Pine as Chief Corporate Development and Strategy Officer

1-10-22

EyePoint and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc. With an Eye on Patients is a trademark of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint, the EyePoint logo, and Delivering Innovation to the Eye are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint, the EyePoint logo, YUTIQ, Durasert, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals, Inc. Verisome is a registered trademark of Ramscor, Inc. All other trademarks are the property of their respective owners.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint, the EyePoint logo, YUTIQ, and Durasert are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint, the EyePoint logo, the YUTIQ logo, and the DEXYCU logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint, the EyePoint logo, YUTIQ, the YUTIQ logo, and Durasert are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint, the EyePoint logo, DEXYCU, and the DEXYCU logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint, the EyePoint logo, Durasert, YUTIQ, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint, the EyePoint logo, YUTIQ, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

04/2021
US-EYP-2100003